13 January 2026
13 January 2026
Shifting regulatory policies and evolving US drug pricing dynamics have created a favourable environment for deals.
Abivax’s lead asset is obefazimod, an anti-inflammatory drug that has produced positive Phase III results.
AbbVie is now one of 16 big pharma companies to sign MFN deals with the Trump administration and commit to the expansion of its US footprint.
AbbVie and RemeGen are the first companies to announce a deal at the J.P Morgan Healthcare Conference 2026, with more deals expected in the coming days.
BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.
Elevidys’ sales missed Q4 analyst estimates, though Sarepta’s CEO Douglas Ingram is confident of a more stable 2026 for the gene therapy.
A new co-innovation lab in the San Francisco Bay area will see Lilly and NVIDIA scientists work alongside each other to fuel drug discovery improvements.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
